CN106491838A - Thorn white glue capsule and its application in treatment leukopenia - Google Patents
Thorn white glue capsule and its application in treatment leukopenia Download PDFInfo
- Publication number
- CN106491838A CN106491838A CN201611160664.XA CN201611160664A CN106491838A CN 106491838 A CN106491838 A CN 106491838A CN 201611160664 A CN201611160664 A CN 201611160664A CN 106491838 A CN106491838 A CN 106491838A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- radix
- medicine
- weight portion
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 39
- 201000002364 leukopenia Diseases 0.000 title claims abstract description 12
- 231100001022 leukopenia Toxicity 0.000 title claims abstract description 12
- 239000003292 glue Substances 0.000 title abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 61
- 230000005855 radiation Effects 0.000 claims abstract description 25
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- -1 absorption carrier Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 241000271039 Agkistrodon Species 0.000 claims 1
- 210000002960 bfu-e Anatomy 0.000 claims 1
- 239000007767 bonding agent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 210000003013 erythroid precursor cell Anatomy 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 210000000130 stem cell Anatomy 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000003394 haemopoietic effect Effects 0.000 abstract description 3
- 206010025482 malaise Diseases 0.000 abstract description 3
- 239000013641 positive control Substances 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 206010020880 Hypertrophy Diseases 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract description 2
- 210000001185 bone marrow Anatomy 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 230000008093 supporting effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000011886 peripheral blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- GTBYFJITPRWOBT-UHFFFAOYSA-N diethyl 1,4-dihydroxynaphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C(O)=C(C(=O)OCC)C(C(=O)OCC)=C(O)C2=C1 GTBYFJITPRWOBT-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 230000002607 hemopoietic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000001395 Acute radiation syndrome Diseases 0.000 description 3
- 206010068142 Radiation sickness syndrome Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses thorn white glue capsule and its application in treatment leukopenia.It is experimentally confirmed：The thorn white glue capsule of the present invention can effectively facilitate 1.0Gy60The recovery of Co gamma-rays total irradiation peripheral hemogram and hematopoietic colonies for three days on end, effect is substantially better than positive control drug 408, by stimulating bone marrow stem/progenitor cells hypertrophy, mitigate its degree of injury, recover peripheral white blood cell, adjust the approach such as body's immunity and reach the therapeutical effect to leukopenia caused by low dose of particularly low dose radiation.The thorn white glue capsule of the present invention not only recovers to truly have curative effect to low dose radiation and radiation sickness later stage, and also there is important function to the supporting and upgrading of filling a vacancy of radiation damage protection medicine.
Description
Technical field
The invention belongs to biological technical field, and in particular to thorn white glue capsule and its answering in treatment leukopenia
With.
Background technology
Leukopenia caused by low dose radiation, according to its primary symptom have weak, dizzy, cardiopalmus, be insomnia, indigestion and loss of appetite food
Less, low grade fever, pharyngalgia, tongue erosion etc., belong to the disease categories such as Chinese medicine " blood deficiency ", " asthenia ", " epidemic febrile disease ".Motherland's medical science thinks, is
Not enough by natural endowment, to lose the day after tomorrow and support, ferritic is lost；Or diseases caused by exogenous pathogenic factor pathogenic factor；Or prolonged illness wrong treatment；Or qi depression to blood stasis；Or by medicine institute
Wound causes QI and blood all empty, and negative and positive are become estranged, and internal organs lose.The traditional Chinese medical science thinks " blood person's foodstuff essence, biochemistry in spleen ", spleen be the day after tomorrow it
This, main transporting, main extremity, main muscle, insufficiency of the spleen not then being good for are transported, and the biochemistry of blood is passive, and appetite is poor, becomes thin, weak.Kidney governing bones, raw
Marrow, hides the essence of five ZANG-organs and six FU-organs gas, is discontented with if kidney deficiency, and blood can not be changed.Then marrow is empty for kidney deficiency, soreness of the waist and knees, seminal emission, tinnitus, vigour
Weak, positive QI-insufficiency, it is weak to defend outer function, and easily being invaded by exogenous pathogen is attacked and fallen ill.Therefore, Most scholars think, primary disease should
Controlled with spleen kidney opinion, strengthening the spleen and nourishing the stomach, enriching yin and nourishing kidney or warming and recuperating the kidney-YANG.Also the scholar having is controlled from the heart, liver opinion, invigorating the heart and spleen, or adjusts liver
The kidney invigorating.
The species of antiradiation drug mainly includes at present：Sulfur-containing compound, immunomodulator, estrogenses, cytokine
Class, calcium antagonist and Chinese herbal medicine etc..But there are many weak points as practical：The potency of sulfur-bearing class radiation prophylactic agent is general
Not strong, current potency most strong compound such as WR-2721 toxicity is very strong；Estrogenses radiation damage protective agents effective dose
For thousands of times of physiological concentration, life-time service side effect is not easily overcome.Treatment acute radiation sickness during, initial stage with
Based on eliminating evil and with righting, when a large amount of heat and toxic materials clearing away medicine are applied using diuretic with heat-clearing and toxic substances removing.In latent phase still with heat clearing away
Based on removing toxic substances, pathogenic fire purging Chinese medicine, using cooling blood for hemostasis, replenishing YIN and removing heat class Chinese medicine.In the obvious Restoration stage of clinical symptoms, dispelled with righting
On the basis of second stage, based on heresy, increase the Chinese medicine of invigorating the liver and kidney, benefiting qi and nourishing blood, benefiting essence and marrow.Chinese medicine is mainly put to acute
Penetrating the hematopoietic repair of disease generation, immunologic function reduces and gastrointestinal dysfunction therapeutical effect.
The equipment of the protection natural drug of radiation damage at present is mainly Rubidate, and existing weaponry and equipment medicine can only solve moderate
Acute radiation sickness prevents and treats problem.
Content of the invention
The technical problem to be solved in the present invention is how to treat or leukopenia that auxiliary treatment low dose radiation causes
Disease.
In order to solve above-mentioned technical problem, present invention firstly provides a kind of medicine.
The composition of the crude drug of the medicine that the present invention is provided is as follows：
Radix Et Caulis Acanthopanacis Senticosi 190-210 weight portion Herba Hedyotidis Diffusae 290-310 weight portion Semen Cuscutae 140-160 weight portions
Fructus Psoraleae 140-160 weight portion Radix Angelicae Sinensis 140-160 weight portion Radix Astragali 190-210 weight portions
Radix Paeoniae Rubra 90-110 weight portion Radix Rehmanniae Preparata 140-160 weight portion Fructus Lycii 140-160 weight portions
Caulis Spatholobi 140-160 weight portions.
In said medicine, the composition for making the crude drug of the medicine is as follows：
200 weight portion Herba Hedyotidis Diffusae of Radix Et Caulis Acanthopanacis Senticosi, 300 weight portion Semen Cuscutae, 150 weight portion
150 weight portion Radix Angelicae Sinensis of Fructus Psoraleae, the 150 weight portion Radix Astragali, 200 weight portion
100 weight portion Radix Rehmanniae Preparata of Radix Paeoniae Rubra, 150 weight portion Fructus Lycii, 150 weight portion
150 weight portion of Caulis Spatholobi.
In said medicine, in the medicine, also contain adjuvant.
In said medicine, the adjuvant is diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption rush
Enter agent, surfactant, absorption carrier, lubricant, correctivess or sweeting agent.
In order to solve above-mentioned technical problem, present invention also offers the method for preparing said medicine.
The method of the preparation said medicine that the present invention is provided comprises the steps：
(1) Radix Et Caulis Acanthopanacis Senticosi 190-210 weight portions water is at least extracted once, collects extracting solution A, concentration obtains extractum；
(2) by Semen Cuscutae 140-160 weight portions, Fructus Psoraleae 140-160 weight portions, Caulis Spatholobi 140-160 weight portions and white
Serpentis SHECAO 290-310 weight portion mixes, and is at least extracted once with ethanol solution, collects extracting solution B, removes the extracting solution B
Middle ethanol, obtains extracting solution C；
(3) by Radix Angelicae Sinensis 140-160 weight portions, Fructus Lycii 140-160 weight portions, Radix Astragali 190-210, Radix Rehmanniae Preparata 140-160 weights
Amount part and the mixing of Radix Paeoniae Rubra 90-110 weight portions, are at least extracted once with water, obtain extracting solution D, and by the extracting solution D with described
Extracting solution C is mixed, concentration, obtains clear paste；
(4) extractum and the clear paste are mixed, that is, obtains the medicine.
In said medicine,
The Radix Et Caulis Acanthopanacis Senticosi is 200 weight portions, the Herba Hedyotidis Diffusae is 300 weight portions, the Semen Cuscutae is 150 weight
Part, the Fructus Psoraleae are 150 weight portions, 150 weight portions, the Radix Astragali of ought being classified as 200 weight portions, the Radix Paeoniae Rubra is
100 weight portions, the Radix Rehmanniae Preparata are 150 weight portions, the Fructus Lycii is 150 weight portions, the Caulis Spatholobi is 150 weight portions.
In said medicine,
In step (1), with water extraction twice, each plus 8 times of amount water, 3 hours every time；
In step (2), extracted three times with ethanol solution, each plus 8 times of amount ethanol solution, 2 hours every time；The ethanol is molten
Liquid is ethanol water that volume fraction is 75%；
In step (3), with water extraction three times, every time plus 10 times of amount water, 3 hours every time；
In step (4), also comprise the steps after the mixing：The mixture that step (4) is obtained is dried to dry powder, then
After the dry powder and dried starch are mixed, load capsulae vacuuses, obtain capsule.
In order to solve above-mentioned technical problem, present invention also offers the new use of the medicine of said medicine or said method preparation
On the way.
The invention provides medicine prepared by said medicine or said method has arbitrary work(in following (1)-(4) in preparation
Application in the product of energy：
(1) treatment or the radiation-induced leukopenia of auxiliary treatment；
(2) number of peripheral blood leucocyte after radiating is improved；
(3) propagation of hemopoietic progenitor cell after promoting to radiate.
In above-mentioned application, the hemopoietic progenitor cell is CFU-GM and/or CFU-E and/or BFU-E and/or CFU-Mix.
In above-mentioned application, the radiation is low dose radiation, and the low dose radiation is specially 1.0Gy60Co gamma-rays spokes
Penetrate.
The present invention prevents and treats problem for what existing weaponry and equipment medicine can only solve moderate acute radiation sickness, sends out from natural drug
Effectively medicine-thorn white glue capsule is recovered really to low dose radiation and radiation sickness middle and late stage now.The thorn white glue capsule of the present invention is selected
, used as monarch drug, Radix Et Caulis Acanthopanacis Senticosi is pungent, slight bitter, temperature, replenishing QI to invigorate the spleen for Radix Et Caulis Acanthopanacis Senticosi, Herba Hedyotidis Diffusae, and tonifying the kidney for tranquilization is mainly used in spleen kidney yang
Void, body void are weak, inappetence, the disease such as soreness of waist and knee joint；Herba Hedyotidis Diffusae is bitter, sweet, cold, heat-clearing and toxic substances removing, the warm-dryness syndrome in restriction side
Product, play the role of preferable leukocyte increasing again；Semen Cuscutae and Fructus Lycii are ministerial drug, can tonifying kidney and nourishing yin replenishing essence, and can QI invigorating
Strengthening the spleen and nourishing the stomach.Full side has nourishing kidney spleen invigorating, the effect that blood-nourishing is enriched blood, temperature compensation within reason, and there is preferable leukocyte increasing
Effect.It is used in particular for preventing and treating radiogenic leukopenia.It is experimentally confirmed：The thorn white glue capsule of the present invention can be effective
Promote 1.0Gy60The recovery of Co gamma-rays total irradiation peripheral hemogram and hematopoietic colonies for three days on end, effect are substantially better than positive right
According to medicine Rubidate, by stimulating bone marrow stem/progenitor cells hypertrophy, mitigate its degree of injury, recover peripheral white blood cell, adjust
The approach such as body's immunity reach the therapeutical effect to leukopenia caused by low dose of particularly low dose radiation.This
Bright thorn white glue capsule not only recovers to truly have curative effect to low dose radiation and radiation sickness later stage, and radiation damage protection medicine is filled a vacancy
Supporting and upgrading also has important function.
Description of the drawings
Fig. 1 is to pierce the impact that white glue capsule irradiates mouse peripheral blood leukocyte to 1.0Gy gamma-rays.
Fig. 2 is to pierce the impact that white glue capsule irradiates the peripheral blood red cell in mice to 1.0Gy gamma-rays.
Fig. 3 is to pierce the impact that white glue capsule irradiates mouse peripheral blood hemoglobin to 1.0Gy gamma-rays.
Fig. 4 irradiates the hematoblastic impact of mouse peripheral blood for thorn white glue capsule to 1.0Gy gamma-rays.
Fig. 5 is the impact that irradiation control group irradiates mice CFU-GM for three days on end to 1.0Gy gamma-rays.
Fig. 6 is to pierce the impact that white glue capsule irradiates mice CFU-GM for three days on end to 1.0Gy gamma-rays.
Fig. 7 is to pierce the impact that white glue capsule irradiates mice CFU-Mix for three days on end to 1.0Gy gamma-rays.
Fig. 8 is the impact that irradiation control group irradiates mice CFU-E for three days on end to 1.0Gy gamma-rays.
Fig. 9 is to pierce the impact that white glue capsule irradiates mice CFU-E for three days on end to 1.0Gy gamma-rays.
Specific embodiment
Experimental technique used in following embodiments if no special instructions, is conventional method.
In following embodiments, material used, reagent etc., if no special instructions, commercially obtain.
Quantitative test in following embodiments, is respectively provided with three times and repeats to test, results averaged.
Hemolysin in following embodiments, diluent and cleanout fluid are the products of Shandong Lan Qiao Science and Technology Ltd.s.
RPMI1640 in following embodiments is the product of Gibco BRL companies.
Hyclone and horse serum in following embodiments is the product of Beijing Military Area Command's veterinary's centre of prevention and cure.
Epo, IL-3, the product of L-glutaminate Jun Shi Sigma companies in following embodiments.
Methylcellulose in following embodiments is the product of Whatman companies.
Test apparatuses used in following embodiments are passed through《Academy of Military Medicine, PLA's metrology and measurement
Stand》Detect qualified, the concurrent quality certification.F820 type cellanalyzers are the products of Japanese Sysmex companies.CO2Incubator is
The product of Thermo Forma companies.
Rubidate in following embodiments document " Song Shuyuan, Ding Linmao, Chen Ying, white jade are precious. Rubidate is to hemopoietic
The impact of function and its toxicity research [J] combination of Chinese and Western medicine magazine .1985.5 (10)：Mistake disclosed in 625-626. ", the public can be from
INST OF EMISSION ＆ RADIATION M obtains.
Embodiment 1, the preparation of thorn white glue capsule
The formula of the thorn white glue capsule (Cibai jiaonang) of the present invention is as follows：Radix Et Caulis Acanthopanacis Senticosi 200g, Herba Hedyotidis Diffusae 300g,
Semen Cuscutae 150g, Fructus Psoraleae 150g, Radix Angelicae Sinensis 150g, Radix Astragali 200g, Radix Paeoniae Rubra 100g, Radix Rehmanniae Preparata 150g, Fructus Lycii 150g, Caulis Spatholobi
150g.Concrete preparation method is as follows：
1st, Radix Et Caulis Acanthopanacis Senticosi 200g is added water to cook twice, adds 8 times of amount water every time, 3 hours every time, collecting decoction was filtered, will filter
Liquid is condensed into extractum, obtains Radix Et Caulis Acanthopanacis Senticosi extractum；
2nd, Semen Cuscutae 150g, Fructus Psoraleae 150g, Caulis Spatholobi 150g and Herba Hedyotidis Diffusae 300g are added 75% ethanol water
It is heated to reflux three times, 8 times of 75% ethanol waters of amount, 2 hours every time, merge ethanol extract, filter, by filtrate decompression every time
Ethanol is reclaimed to without alcohol taste, extracting solution is obtained；
3rd, Radix Angelicae Sinensis 150g, Fructus Lycii 150g, Radix Astragali 200g, Radix Rehmanniae Preparata 150g and Radix Paeoniae Rubra 100g are added water to cook three times, every time
Plus 10 times of amount water, 3 hours every time, collecting decoction filtered, and filtrate is merged with the extracting solution that step 2 is obtained, and was concentrated into relative
Clear paste of the density for 1.20-1.25 (50 DEG C)；
4th, the clear paste that the Radix Et Caulis Acanthopanacis Senticosi extractum and step 3 for obtaining step 1 is obtained merges, and is dried to dry powder, and adds appropriate
Dried starch (mass fraction is 20-25%), mix, load capsule, make 1000, obtain final product the present invention thorn white glue capsule.
The application of embodiment 2, thorn white glue capsule in the leukopenia that treatment low dose radiation causes
The present invention is by observing thorn white glue capsule to 1.0Gy60Co γ lines for three days on end total irradiation mouse peripheral blood leukocyte,
The impact of CFU-GM, CFU-Mix, BFU-E, CFU-E, studies its treatment for reducing disease to low dose exposure murine interleukin and makees
With.Comprise the following steps that：
(1) experiment material and method
1st, experiment material
BALB/C mice, 5-6 week old, body weight 16-20g.Quality of Experimental Animals quality certification number SCXK- (army) 2007-004,
Animal facility credit number SYXK- (army) 2007-004.
2nd, experimental technique
Experiment BALB/C mice 78, female 48, male 30.Wherein per group of hematological index 10, totally 60,
Male and female half and half；Hemopoietic progenitor cell culture 3 per group, female, totally 18.First weigh after raising 3-5 days, survey normal peripheral blood white
Cell number.Through60Co gamma-rays total irradiations, dosage is 1.0Gy, Continuous irradiation 3 days, and close rate is respectively 211.33cGy.min-1、211.25cGy.min-1、211.18cGy.min-1.Gastric infusion by after irradiation, continuous 14 days, matched group was when corresponding
Between in give isopyknic distilled water.Each group the 1st, 4,7,11,14,17,21 days detection peripheral bloods after pre-irradiation, irradiation
Leukocyte count, and carry out CFU-Mix, CFU-GM, BFU-E, CFU-E cell culture in the 7th day after irradiation.
It is divided into following six groups according to administration difference：
Normal group：It is not irradiated；Give isopyknic distilled water in the corresponding time, 0.25ml/ only, daily
1 time, continuous 14 days；
Irradiation control group：Through60Co gamma-rays total irradiations, dosage are 1.0Gy, and Continuous irradiation was not administered after 3 days, corresponding
Time in give isopyknic distilled water, 0.25ml/ only, once a day, continuous 14 days；
Radix Rubiae matched group (positive control)：Through60Co gamma-rays total irradiations, dosage is 1.0Gy, and Continuous irradiation 3 days is laggard
Row gastric infusion, medicine are Rubidate (tablet), and dosage is 125mg/kg, once a day, continuous 14 days；
Pierce white high dose group：Through60Co gamma-rays total irradiations, dosage is 1.0Gy, and Continuous irradiation carries out gavage after 3 days and gives
Medicine, medicine are the thorn white glue capsule prepared in step one, and dosage is 30g/kg, once a day, continuous 14 days；
Pierce white middle dose group：Through60Co gamma-rays total irradiations, dosage is 1.0Gy, and Continuous irradiation carries out gavage after 3 days and gives
Medicine, medicine are the thorn white glue capsule prepared in step one, and dosage is 15g/kg, once a day, continuous 14 days；
Pierce white low dose group：Through60Co gamma-rays total irradiations, dosage is 1.0Gy, and Continuous irradiation carries out gavage after 3 days and gives
Medicine, medicine are the thorn white glue capsule prepared in step one, and dosage is 7.5g/kg, once a day, continuous 14 days.
(2) Indexs measure
1st, peripheral hemogram detection
10 per group, male and female half and half, respectively 1,3,5,7,11,14,15,17,21 days after pre-irradiation, irradiation, per only little
Caudal vein takes 20 μ l of blood.With F820 type Blood cell analyzer detection peripheral hemograms.
(1) peripheral blood leucocyte
Compare with irradiation control group, the 7th day leukocyte count is significantly raised positive drug Rubidate after irradiation, of the invention
The 4-7 days leukocyte counts are also significantly raised after irradiation to pierce white high dose group, (p<0.05, table 1, Fig. 1), and apparently higher than the positive
Matched group.Illustrate that the thorn white glue capsule of the present invention can improve mouse peripheral blood leukocyte count after irradiation, it is white that treatment radiation causes
Cytopenia.
Table 1, thorn white glue capsule 1.0Gy gamma-rays are irradiated for three days on end after mouse peripheral blood leukocyte (109/ L) impact
Note：Compare with irradiation control group, * p<0.05；Compare with positive controls, #p<0.05；N=10, similarly hereinafter.
(2) peripheral red blood cells and hemoglobin
After irradiation, the erythrocyte of each group, hemoglobin present and first rise the trend for declining afterwards and gradually recovering, but with just
Often matched group compares no difference of science of statistics (table 2, table 3, Fig. 2, Fig. 3).Illustrate the thorn white glue capsule of the present invention to erythrocyte and blood
Lactoferrin is without remarkable effect.
Table 2, thorn white glue capsule irradiate the peripheral blood red cell in mice (10 for three days on end to 1.0Gy gamma-rays12/ L) impact
Table 3, thorn white glue capsule irradiate the impact of mouse peripheral blood hemoglobin (g/L) for three days on end to 1.0Gy gamma-rays
(3) platelet count
Irradiation control and the platelet of other medication groups, assume downward trend after first rising for 1 day, according to after after irradiation
Reach minimum within 7 days, hereafter slow rise.Wherein, the 1st day platelet count is notable after irradiation for the white high dose group of thorn and low dose group
Raise, the 1st day platelet count significantly raises (p to positive drug Rubidate after irradiation<0.05, table 4, Fig. 4).Illustrate the present invention's
Thorn white glue capsule can improve mouse peripheral blood number of platelets after irradiation.
Table 4, thorn white glue capsule irradiate mouse peripheral blood platelet (10 for three days on end to 1.0Gy gamma-rays9/ L) impact
Note：Compare with irradiation control group, * p<0.05, * * * p<0.001, n=10.
2nd, mouse hemopoietic CFU-GM affects
Reference literature " Liu Xiuzhen. hemopoietic progenitor cell culture technique laboratory manual. Beijing：Beijing Publishing House, 1993.25-
133 " method in carries out Colony cultivation, counts each group mouse hemopoietic CFU-GM number：CFU-GM (granular leukocyte macrophage colonies
Generate unit), CFU-E (erythrocytic colony-forming unit), BFU-E (erythrocytic burst-forming unit), CFU-Mix
(mixed colony-forming unit)；And the measurement result with all animal different times of Microsoft excel inputs, calculate each group
The significant t-test of mean between mean, standard deviation and group.Comprise the following steps that：
(1) after irradiating, 7 days cervical dislocations put to death mice, 3 per group, female.Put immersion a moment in 75% ethanol to sterilize, take
Mouse femur, goes out medullary cell with RPMI RPMI-1640s, crosses No. 4 syringe needles and makes single cell suspension, counts cell and calculates
Inoculating cell amount, by inoculation nucleated cell 5 × 105/ ml system computings.
(2) with the grain system system (cell 1 × 10 that horse serum 2ml, G-CSF 100ng, step (1) are obtained5/ml、RPMI
RPMI-1640 is mended to 7.6ml), after 10min being preheated with thermostatic water-bath method under the conditions of 37 DEG C, add 5% in grain system system
Boil agar 0.5ml to mix immediately, quick mixing is shaken with 5ml syringes side edged.Above-mentioned system 1ml is instilled per ware, a modeling is put
In magazine and after putting several plates for adding water, in 37 DEG C, 5%CO2Under conditions of culture 6 days observation count CFU-GM, more than 50
Individual cell is a cell colony.
(3) match somebody with somebody red system, (concentration is 10 to mixed stocker cultivating system-4The mercaptoethanol 0.2ml of M, mass fraction are 3% L-
Glutamine 0.03ml, horse serum 0.7ml, Epo 4U, IL-3 60ng, the methylcellulose 0.7ml that mass fraction is 2.7%,
The cell 1 × 10 that step (1) is obtained6/ ml), agitator is mixed, and is added in 24 orifice plates, per hole 0.2ml, in 37 DEG C, 5%CO2's
Under the conditions of culture 3 days observation count CFU-E and CFU-GM, more than 50 cells be a cell colony.In 37 DEG C, 5%CO2's
Under the conditions of culture 7 days observation count BFU-E, CFU-mix.
As a result as shown in table 5, Fig. 5, Fig. 6, Fig. 7, Fig. 8 and Fig. 9.Compare with irradiation control group, white high dose group is pierced with sun
Property control Rubidate group irradiation 7 after promote CFU-GM, CFU-E propagation (p<0.05-0.001)；But pierce white high dose group
Simultaneously facilitate BFU-E, CFU-Mix propagation (p<0.05-0.01).Illustrate that the thorn white glue capsule of the present invention can promote mice after irradiation
CFU-GM, CFU-E, BFU-E and CFU-Mix breed.
Table 5, thorn white glue capsule irradiate the impact of mouse hemopoietic CFU-GM for three days on end to 1.0Gy gamma-rays
Note：Compare with irradiation control group, * p<0.05, * * p<0.01, * * * p<0.001.
By above-mentioned it is demonstrated experimentally that mice is through 1.0Gy60After Co gamma-rays total irradiation 3 days, leukocyte is down to normal value
50-60% or so, the 7th day leukocyte count is significantly raised positive drug Rubidate after irradiation, simultaneously facilitate CFU-GM and
CFU-E breeds, and the 1-7 days leukocyte counts significantly raise (p to the thorn white glue capsule of the present invention after irradiation<0.05)；7 days after irradiation
Promote CFU-GM, CFU-E, BFU-E and CFU-Mix propagation (p<0.05-0.001).Illustrate the thorn white glue capsule of the present invention in irradiation
Early stage can improve peripheral white blood cell afterwards, and promote CFU-GM, CFU-E, BFU-E and CFU-Mix to breed.
Claims (10)
1. a kind of medicine, the composition for making the crude drug of the medicine are as follows：
Radix Et Caulis Acanthopanacis Senticosi 190-210 weight portion Herba Hedyotidis Diffusae 290-310 weight portion Semen Cuscutae 140-160 weight portions
Fructus Psoraleae 140-160 weight portion Radix Angelicae Sinensis 140-160 weight portion Radix Astragali 190-210 weight portions
Radix Paeoniae Rubra 90-110 weight portion Radix Rehmanniae Preparata 140-160 weight portion Fructus Lycii 140-160 weight portions
Caulis Spatholobi 140-160 weight portions.
2. medicine according to claim 1, it is characterised in that：The composition for making the crude drug of the medicine is as follows：
200 weight portion Herba Hedyotidis Diffusae of Radix Et Caulis Acanthopanacis Senticosi, 300 weight portion Semen Cuscutae, 150 weight portion
150 weight portion Radix Angelicae Sinensis of Fructus Psoraleae, the 150 weight portion Radix Astragali, 200 weight portion
100 weight portion Radix Rehmanniae Preparata of Radix Paeoniae Rubra, 150 weight portion Fructus Lycii, 150 weight portion
150 weight portion of Caulis Spatholobi.
3. medicine according to claim 1 and 2, it is characterised in that：Also contain adjuvant in the medicine.
4. medicine according to claim 3, it is characterised in that：The adjuvant is diluent, excipient, filler, bonding
Agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant, correctivess or sweeting agent.
5. the method for preparing the medicine described in claim 1, comprises the steps：
(1) Radix Et Caulis Acanthopanacis Senticosi 190-210 weight portions water is at least extracted once, collects extracting solution A, concentration obtains extractum；
(2) by Semen Cuscutae 140-160 weight portions, Fructus Psoraleae 140-160 weight portions, Caulis Spatholobi 140-160 weight portions and Agkistrodon
SHECAO 290-310 weight portion mixes, and is at least extracted once with ethanol solution, collects extracting solution B, removes second in the extracting solution B
Alcohol, obtains extracting solution C；
(3) by Radix Angelicae Sinensis 140-160 weight portions, Fructus Lycii 140-160 weight portions, Radix Astragali 190-210, Radix Rehmanniae Preparata 140-160 weight portions
Mix with Radix Paeoniae Rubra 90-110 weight portions, at least extracted once with water, obtain extracting solution D, and by the extracting solution D and the extraction
Liquid C is mixed, concentration, obtains clear paste；
(4) extractum and the clear paste are mixed, that is, obtains the medicine.
6. method according to claim 5, it is characterised in that：
The Radix Et Caulis Acanthopanacis Senticosi is 200 weight portions, the Herba Hedyotidis Diffusae is 300 weight portions, the Semen Cuscutae is 150 weight portions, institute
State Fructus Psoraleae for 150 weight portions, described when be classified as 150 weight portions, the Radix Astragali for 200 weight portions, the Radix Paeoniae Rubra be 100 weight
Part, the Radix Rehmanniae Preparata are 150 weight portions, the Fructus Lycii is 150 weight portions, the Caulis Spatholobi is 150 weight portions.
7. the method according to claim 4 or 5, it is characterised in that：
In step (1), with water extraction twice, each plus 8 times of amount water, 3 hours every time；
In step (2), extracted three times with ethanol solution, each plus 8 times of amount ethanol solution, 2 hours every time；The ethanol solution is
Volume fraction is 75% ethanol water；
In step (3), with water extraction three times, every time plus 10 times of amount water, 3 hours every time；
In step (4), also comprise the steps after the mixing：The mixture that step (4) is obtained is dried to dry powder, then by institute
After stating dry powder and dried starch mixing, load capsulae vacuuses, obtain capsule.
8. the medicine that in arbitrary described medicine or claim 5-7 prepared by arbitrary described method in claim 1-4 is in system
Getting everything ready has application in following (1)-(4) in the product of arbitrary function：
(1) treatment or the radiation-induced leukopenia of auxiliary treatment；
(2) number of peripheral blood leucocyte after radiating is improved；
(3) propagation of hemopoietic progenitor cell after promoting to radiate.
9. application according to claim 8, it is characterised in that：The hemopoietic progenitor cell be CFU-GM and/or CFU-E and/
Or BFU-E and/or CFU-Mix.
10. application according to claim 8 or claim 9, it is characterised in that：The radiation is low dose radiation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611160664.XA CN106491838A (en) | 2016-12-15 | 2016-12-15 | Thorn white glue capsule and its application in treatment leukopenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611160664.XA CN106491838A (en) | 2016-12-15 | 2016-12-15 | Thorn white glue capsule and its application in treatment leukopenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106491838A true CN106491838A (en) | 2017-03-15 |
Family
ID=58331100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611160664.XA Pending CN106491838A (en) | 2016-12-15 | 2016-12-15 | Thorn white glue capsule and its application in treatment leukopenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491838A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737715A (en) * | 2022-10-08 | 2023-03-07 | 中央民族大学 | A Chinese medicinal composition with leukocyte increasing effect |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277034A (en) * | 2000-06-09 | 2000-12-20 | 中国人民解放军军事医学科学院放射医学研究所 | Chinese medicine preparation |
| CN102048902A (en) * | 2010-12-22 | 2011-05-11 | 中国人民解放军第三○二医院 | Traditional Chinese medicine preparation and traditional Chinese medicine extract as well as preparation method, application and formulation of traditional Chinese medicine extract |
| CN102258626A (en) * | 2010-05-28 | 2011-11-30 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof |
| CN102755445A (en) * | 2012-08-21 | 2012-10-31 | 河南天方药业中药有限公司 | Chinese materia medica preparation for treating leukocytopenia and preparation process thereof |
-
2016
- 2016-12-15 CN CN201611160664.XA patent/CN106491838A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277034A (en) * | 2000-06-09 | 2000-12-20 | 中国人民解放军军事医学科学院放射医学研究所 | Chinese medicine preparation |
| CN102258626A (en) * | 2010-05-28 | 2011-11-30 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof |
| CN102048902A (en) * | 2010-12-22 | 2011-05-11 | 中国人民解放军第三○二医院 | Traditional Chinese medicine preparation and traditional Chinese medicine extract as well as preparation method, application and formulation of traditional Chinese medicine extract |
| CN102755445A (en) * | 2012-08-21 | 2012-10-31 | 河南天方药业中药有限公司 | Chinese materia medica preparation for treating leukocytopenia and preparation process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李彬之 等: "《现代中医奇效良方宝典（上）》", 31 March 1993, 上海科学普及出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737715A (en) * | 2022-10-08 | 2023-03-07 | 中央民族大学 | A Chinese medicinal composition with leukocyte increasing effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078512A (en) | Pharmaceutical composition for improving fatigue and preparation method thereof | |
| CN101375968B (en) | Chinese medicinal composition as well as preparation method and application thereof | |
| CN108402460A (en) | A kind of multifunctional food composition and preparation method thereof increasing bone density | |
| CN102526326B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN107789484B (en) | Traditional Chinese medicine composition for treating irregular menstruation and preparation method thereof | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN102961636B (en) | Pure traditional Chinese medicine composition for treating poultry infectious bursal disease and preparation method thereof | |
| CN106491838A (en) | Thorn white glue capsule and its application in treatment leukopenia | |
| GB2581592A (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| CN103142766B (en) | Medicine for controlling coccidiosis in rabbits | |
| CN102727693B (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN103923804A (en) | Pine needle ferment body-building health wine | |
| CN108114047A (en) | A kind of Chinese medicine composition for treating reflux esophagitis | |
| CN112516276A (en) | Traditional Chinese medicine for preventing novel coronavirus pneumonia, preparation process thereof and traditional Chinese medicine beverage | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN103877375B (en) | Traditional Chinese medicine for treating blocking antibody deficient recrudescence spontaneous abortion (RSA) and preparation method thereof | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN103446571B (en) | Drug for dispelling dampness and losing weight | |
| CN108096551A (en) | A kind of Chinese medicine preparation of cure scapulohumeral periarthritis | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN104758719A (en) | Traditional Chinese medicinal composition for treating leucocytopenia, granule thereof, and preparation methods of composition and granule | |
| CN105535138A (en) | Traditional Chinese medicine preparation for treating hepatic fibrosis and preparation method thereof | |
| CN104435468A (en) | Traditional Chinese medicine powder for preventing and controlling infectious serositis of ducks | |
| CN105707883B (en) | Crow pheasant composition and the preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |
|
| RJ01 | Rejection of invention patent application after publication |